Topiramate increases the risk of valproic acid-induced encephalopathy

Epilepsia

Volumn 54, Issue 1, 2013, Pages

  Noh, Young ^a   Kim, Dong Wook ^b   Chu, Kon ^c   Lee, Soon Tae ^c   Jung, Keun Hwa ^c   Moon, Hye Jin ^c   Lee, Sang Kun ^c  

^a Sungkyunkwan University   (South Korea)

^b Konkuk University School of Medicine   (South Korea)

^c Seoul National University Hospital   (South Korea)

Author keywords

Adverse effects; Incidence; Topiramate; Valproic acid

Indexed keywords

AMMONIA; LACTULOSE; TOPIRAMATE; VALPROIC ACID;

ADULT; AGED; AMMONIA BLOOD LEVEL; ARTICLE; BRAIN DISEASE; CLINICAL FEATURE; CONFUSION; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK; TREATMENT DURATION;

ADULT; AGED; ANTICONVULSANTS; BRAIN DISEASES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ELECTROENCEPHALOGRAPHY; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; VALPROIC ACID; YOUNG ADULT;

EID: 84872054348     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2012.03532.x     Document Type: Article

References (12)

1. Cheung E, Wong V, Fung C-W,. (2005) Topiramate-valproate-induced hyperammonemic encephalopathy syndrome: case report. J Child Neurol 19: 157-160.
2. Dealberto MJ,. (2007) Valproate-induced hyperammonaemic encephalopathy: review of 14 cases in the psychiatric setting. Int Clin Psychopharmacol 22: 330-337.
3. Deutsch S, Burket JA, Rosse RB,. (2009) Valproate-induced hyperammonemic encephalopathy and normal liver function: possible synergism with topiramate. Clin Neuropharmacol 32: 350-352.
4. Fan CC, Huan MC, Liu HC,. (2008) Lamotrigine might potentiate valproic acid-induced hyperammonemic encephalopathy. Prog Neuropsychopharmacol Biol Psychiatry 32: 1747-1748.
5. Gerstner T, Buesing D, Longin E, Bendl C, Wenzel D, Scheid B, Goetze G, Macke A, Lippert G, Klostermann W, Mayer G, Augspach-Hofmann R, Fitzek S, Haensch C-A, Reuland M, Koenig SA,. (2006) Valproic acid encephalopathy-19 new cases in Germany from 1994 to 2003-a side effect associated to VPA therapy not only in young children. Seizure 15: 443-448.
6. Gomceli YB, Kutlu G, Cavdar L, Sandivar F, Inan LE,. (2007) Different clinical manifestations of hyperammonemic encephalopathy. Epilepsy Behav 10: 582-587.
7. Gomez-Ibanez A, Urrestarazu-Bolumburu E, Viteri-Torres C,. (2011) Hyperammonemic encephalopathy related to valproate, phenobarbital, and topiramate synergism. Epilepsy Behav 21: 480-482.
8. Hamer H, Knake S, Schomburg U, Rosenow F,. (2000) Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology 54: 230-237.
9. Latour P, Biraben A, Polard E, Bentue-Ferrer D, Beauplet A, Tribut O, Allain H,. (2004) Drug induced encephalopathy in six epileptic patients: topiramate? valproate? or both? Hum Psychopharmacol 19: 193-203.
10. Longin E, Teich M, Koelfen W, Koenig S,. (2002) Topiramate enhances the risk of valproate-associated side effects in three children. Epilepsia 43: 451-454.
11. Wang V, Saab S,. (2003) Ammonia levels and the severity of hepatic encephalopathy. Am J Med 114: 237-238.
12. Warter JM, Marescaux C, Brandt C, Rumbach L, Micheletti G, Chabrier G, Imler M, Kurtz D,. (1983) Sodium valproate associated with phenobarbital: effects on ammonia metabolism in humans. Epilepsia 24: 628-633.